Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes

Rheumatoid Arthritis Clinical Trial

Official title: Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes

Status Withdrawn

Clinical Trial Summary

Rheumatoid arthritis is a common chronic destructive arthritis. Major pathology change in rheumatoid arthritis is synovium hyperplasia with bone and cartilage erosion. Infiltrates in synovial tissue included type one and type two synoviocytes, B cells, T cells and fibroblasts. These cells will release many cytokines and chemokines, which will induce expression of adhesion molecules, release of variable enzyme from fibroblast and osteoclast and result in bone erosion.

Recent study revealed that fibroblast-like synoviocytes (FLS) have some role in pathogenesis of rheumatoid arthritis.We believed CXCL12/CXCR4 ligand/receptor pair is important in chronicity of rheumatoid arthritis.

CXCL12 polymorphism is studied in many disease. There is no related CXCL12 polymorphism study in rheumatoid arthritis. Our study intended to clarify the relationship between pathology, serology factor, CXCL12 polymorphism in rheumatoid arthritis in hope that new direction of therapy will be elucidated.

Clinical Trial Description

Rheumatoid arthritis is a common chronic destructive arthritis. Many patients suffered from disability from this disease. There is no satisfactory therapy for every patient. Present prognostic factor only explained the disease course partially.

Major pathology change in rheumatoid arthritis is synovium hyperplasia with bone and cartilage erosion. Infiltrates in synovial tissue included type one and type two synoviocytes, B cells, T cells and fibroblasts. These cells will release many cytokines and chemokines, which will induce expression of adhesion molecules, release of variable enzyme from fibroblast and osteoclast and result in bone erosion.

Previous study in rheumatoid arthritis focused mainly in role of lymphocytes and osteoclast. Recent study revealed that fibroblast-like synoviocytes (FLS) have some property which is similar but not identical to dendritic cells in lymph nodes. They are also important provider of IL-7 and IL-15 and play an important role in persisted activation of synovial tissue. Fibroblast will guide B cell infiltration and has intimate mutual interaction with T cells.

Stromal derived growth factor/CXCL12 is an effective lymphocyte chemokine. CXCR4 is corresponding receptor. CXCL12 has been associated with autoantibody production in lupus murine model animal. FLS can express stromal cell-derived factor 1 SDF-1/CXCL12, inducing persisted infiltration of CD4+ and CD8+ T cell. Furthermore, migration, proliferation and matrix mental proteinase secretion of FLSis regulated by CC and CXC chemokine. CXCL12 production by SLF is regulated by TNF-alpha, IL-1beta, and TGF-beta1, but there is still some inconsistency in literatures. CXCL12 itself also induce expression of CXCR4 and secretion of IL-6, IL-8 in FLS. Express of CCR4 in T cell is regulated by IL-2,IL-4,IL-7,IL-10 and cell contact. CXCL12 produced by SLF is also presented by endothelium cell and inducing angiogenesis. Clinical study also indicated that CXCL12 level is related to cartilage destruction. CXCL12 level is decreased after synovectomy. Therefore we believed CXCL12/CXCR4 ligand/receptor pair is important in chronicity of rheumatoid arthritis.

Recently CXCL12 polymorphism is studied in many disease, such as prognosis of HIV patients、chronic myeloproliferative disease, and AML metastasis. There is no related CXCL12 polymorphism study in rheumatoid arthritis. Our study intended to clarify the relationship between pathology, serology factor, CXCL12 polymorphism in rheumatoid arthritis in hope that new direction of therapy will be elucidated. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Arthritis, Rheumatoid
• Rheumatoid Arthritis

• NCT number: NCT00845949
• Study type: Observational
• Source: Far Eastern Memorial Hospital
• Status: Withdrawn
• Phase: N/A
• Start date: November 2006
• Completion date: June 2008